Hone Health
The mass-market men's telehealth platform that pulled TRT out of the urology clinic and into the iPhone.
The men's telehealth platform that pulled TRT out of the urology clinic and into the iPhone — and the one most buyers compare everything else against.
Hone Health is what most buyers actually mean when they Google "online TRT." Founded 2020, scaled hard through 2022-2024 paid acquisition, and built the playbook every newer entrant is now copying: at-home blood draw, telehealth visit, prescription if labs and symptoms align, ongoing monitoring through a clean app.
What it tracks well: testosterone (total + free), estradiol, SHBG, and the standard supporting markers. Members can compare panels over time, see protocol adjustments alongside lab movement, and message clinicians without re-explaining their history every visit. It's the cleanest UX in the category and the lowest-friction entry point for buyers who don't want to navigate a urology referral.
Where it wins: scale and price discipline. The $45 assessment plus $129-149/mo membership lands well under what most buyers pay for in-person TRT after copays, lab fees, and follow-up visits. The app handles refills, dose adjustments, and recurring labs without requiring a new appointment each cycle.
Where it loses: depth and customization. Marek Health and Maximus both go further on protocol complexity (HCG, anastrozole, enclomiphene combos), and clinic-based providers like Defy Medical or Cenegenics will run far broader peptide and ancillary protocols Hone won't prescribe. Hone is deliberately mass-market — that's the strength and the ceiling.
The other consideration is state availability. Telehealth TRT regulations vary widely, and Hone's footprint shifts as state-level rules evolve. Buyers in restrictive states should confirm coverage before committing.
Who should buy: men 30-55 with mid-range symptomatic testosterone who want a clean, well-supported entry to monitored TRT without pre-existing clinic relationships. Who shouldn't: anyone wanting complex multi-medication protocols, anyone in a state with restricted telehealth scope, or anyone who already has an in-network endocrinologist running the same labs for less out-of-pocket.
Men 30-55 with mid-range symptomatic testosterone who want the cleanest mainstream entry into monitored TRT — no urology referral, no in-person visit, app-driven protocol management.
You want complex multi-drug protocols (Marek or Maximus go deeper), you live in a restricted-telehealth state, or you already have an in-network endocrinologist running comparable labs.
Pros
- Lowest-friction entry into monitored TRT — at-home draw, telehealth visit, prescription if eligible
- Cleanest app UX in the category — protocol changes track alongside lab movement over time
- Sharp pricing — $45 assessment, $129-149/mo membership undercuts most clinic-based TRT
- Broadest state availability among consumer TRT telehealth platforms
- Membership covers ongoing labs, refills, and clinician messaging without per-visit fees
- Strong consumer brand recognition — easiest platform to recommend to TRT-curious friends
- No prior endocrinologist or urology relationship required
- Consistent panel set makes year-over-year tracking straightforward
- Mobile-first refill and dose-adjustment workflow handles most member needs without phone calls
Cons
- Mass-market protocol scope — won't run aggressive HCG/anastrozole/peptide stacks (Marek and Maximus do)
- State-by-state telehealth scope varies and changes — confirm coverage before committing
- Less clinical customization than Defy Medical, Cenegenics, or in-person endocrinology
- Pricing tier separates medication cost from membership — total monthly cost can exceed expectations
- Limited support for women's HRT and broader hormone optimization use cases
- Heavy paid-acquisition model — review skew toward early-funnel buyers vs long-term members